Trial Profile
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2020
Price :
$35
*
At a glance
- Drugs Pemafibrate (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms PROMINENT-Eye Ancillary Study
- 03 Apr 2019 Status changed from recruiting to discontinued.
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.
- 20 Nov 2017 New trial record